Terms: = Lung cancer AND CTNNB1, P35222, 1499, ENSG00000168036, CTNNB AND Treatment
38 results:
1. Comprehensive Genomic Analysis of Patients With Non-Small-Cell lung cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.
Wang HY; Ho CC; Lin YT; Liao WY; Chen CY; Shih JY; Yu CJ
JCO Precis Oncol; 2024 Jan; 8():e2300314. PubMed ID: 38190582
[TBL] [Abstract] [Full Text] [Related]
2. Diagnostic Utility of Next-Generation Sequencing in Circulating Free DNA and a Comparison With Matched Tissue in Gallbladder Carcinoma.
Mishra S; Srivastava P; Pandey A; Shukla S; Agarwal A; Husain N
Lab Invest; 2024 Feb; 104(2):100301. PubMed ID: 38092180
[TBL] [Abstract] [Full Text] [Related]
3. Modified Bushen Yiqi formula enhances antitumor immunity by reducing the chemotactic recruitment of M2-TAMs and PMN-MDSCs in Lewis lung cancer-bearing mice.
Kong Q; Zhu H; Gong W; Deng X; Liu B; Dong J
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117183. PubMed ID: 37739106
[TBL] [Abstract] [Full Text] [Related]
4. Whole exome sequencing and MicroRNA profiling of lung adenocarcinoma identified risk prediction features for tumors at stage I and its substages.
Ho H; Yu SL; Chen HY; Yuan SS; Su KY; Hsu YC; Hsu CP; Chuang CY; Chang YH; Li YC; Cheng CL; Chang GC; Yang PC; Li KC
Lung Cancer; 2023 Oct; 184():107352. PubMed ID: 37657238
[TBL] [Abstract] [Full Text] [Related]
5. Papillary thyroid carcinoma with desmoid-type fibromatosis: the clinicopathological features with characteristic imaging and molecular correlation requiring comprehensive treatment.
Huang H; Li L; Liu X; Zhao L; Cui Z; Zhang R; Chen S
Hum Pathol; 2023 Jun; 136():84-95. PubMed ID: 37019411
[TBL] [Abstract] [Full Text] [Related]
6. Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib.
Kunishige M; Ichihara S; Kadota N; Okano Y; Machida H; Hatakeyama N; Naruse K; Shinohara T; Takeuchi E
Thorac Cancer; 2023 Feb; 14(4):423-426. PubMed ID: 36519636
[TBL] [Abstract] [Full Text] [Related]
7. The Mutational Landscape of cancer's Vulnerability to Ionizing Radiation.
Gopal P; Yard BD; Petty A; Lal JC; Bera TK; Hoang TQ; Buhimschi AD; Abazeed ME
Clin Cancer Res; 2022 Dec; 28(24):5343-5358. PubMed ID: 36222846
[TBL] [Abstract] [Full Text] [Related]
8. Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven lung Tumorigenesis.
Vaishnavi A; Juan J; Jacob M; Stehn C; Gardner EE; Scherzer MT; Schuman S; Van Veen JE; Murphy B; Hackett CS; Dupuy AJ; Chmura SA; van der Weyden L; Newberg JY; Liu A; Mann K; Rust AG; Weiss WA; Kinsey CG; Adams DJ; Grossmann A; Mann MB; McMahon M
Cancer Res; 2022 Nov; 82(22):4261-4273. PubMed ID: 36112789
[TBL] [Abstract] [Full Text] [Related]
9. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
Powell CA; Modi S; Iwata H; Takahashi S; Smit EF; Siena S; Chang DY; Macpherson E; Qin A; Singh J; Taitt C; Shire N; Camidge DR
ESMO Open; 2022 Aug; 7(4):100554. PubMed ID: 35963179
[TBL] [Abstract] [Full Text] [Related]
10. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell lung cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract] [Full Text] [Related]
11. Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion lung cancer.
Hellyer JA; White MN; Gardner RM; Cunanan K; Padda SK; Das M; Ramchandran K; Neal JW; Wakelee HA
Clin Lung Cancer; 2022 May; 23(3):264-272. PubMed ID: 34838441
[TBL] [Abstract] [Full Text] [Related]
12. Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma.
Fisk JN; Mahal AR; Dornburg A; Gaffney SG; Aneja S; Contessa JN; Rimm D; Yu JB; Townsend JP
Cancer Lett; 2022 Feb; 526():346-351. PubMed ID: 34780851
[TBL] [Abstract] [Full Text] [Related]
13. CITED4 enhances the metastatic potential of lung adenocarcinoma.
Zhang L; Wang Y; Sha Y; Zhang B; Zhang R; Zhang H; Xu S; Wang H; Xu Y; Chen Y; Zhao X; Zhu J; Zhang Z; Wang C
Thorac Cancer; 2021 May; 12(9):1291-1302. PubMed ID: 33759374
[TBL] [Abstract] [Full Text] [Related]
14. Long Noncoding RNA LINC01006 Facilitates Cell Proliferation, Migration, and Epithelial-Mesenchymal Transition in lung Adenocarcinoma via Targeting the MicroRNA 129-2-3p/ctnnb1 Axis and Activating Wnt/β-Catenin Signaling Pathway.
Zhang Y; Liu H; Zhang Q; Zhang Z
Mol Cell Biol; 2021 May; 41(6):e0038020. PubMed ID: 33753463
[TBL] [Abstract] [Full Text] [Related]
15. Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.
Volckmar AL; Christopoulos P; Kirchner M; Allgäuer M; Neumann O; Budczies J; Rempel E; Horak P; Glade J; Goldschmid H; Seker-Cin H; Brandt R; Kriegsmann M; Leichsenring J; Winter H; Faehling M; Fischer JR; Heußel CP; Herth F; Brummer T; Fröhling S; Schirmacher P; Thomas M; Endris V; Penzel R; Kazdal D; Bochtler T; Stenzinger A
Lung Cancer; 2021 Apr; 154():131-141. PubMed ID: 33667718
[TBL] [Abstract] [Full Text] [Related]
16. Clinical application of next-generation sequencing for the management of desmoid tumors: A case report and literature review.
Lee JM; Kim HG; Shin SY; Lee SH
Medicine (Baltimore); 2021 Jan; 100(1):e24238. PubMed ID: 33429825
[TBL] [Abstract] [Full Text] [Related]
17. Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell lung cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).
Li XM; Li WF; Lin JT; Yan HH; Tu HY; Chen HJ; Wang BC; Wang Z; Zhou Q; Zhang XC; Su J; Chen RL; Wu YL; Yang JJ
Clin Lung Cancer; 2021 Mar; 22(2):100-109.e3. PubMed ID: 33317922
[TBL] [Abstract] [Full Text] [Related]
18. Targeted Next-Generation Sequencing Analysis for Recurrence in Early-Stage lung Adenocarcinoma.
Kim IA; Hur JY; Kim HJ; Park JH; Hwang JJ; Lee SA; Lee SE; Kim WS; Lee KY
Ann Surg Oncol; 2021 Jul; 28(7):3983-3993. PubMed ID: 33140254
[TBL] [Abstract] [Full Text] [Related]
19. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with
Ortiz-Cuaran S; Mezquita L; Swalduz A; Aldea M; Mazieres J; Leonce C; Jovelet C; Pradines A; Avrillon V; Chumbi Flores WR; Lacroix L; Loriot Y; Westeel V; Ngo-Camus M; Tissot C; Raynaud C; Gervais R; Brain E; Monnet I; Giroux Leprieur E; Caramella C; Mahier-Aït Oukhatar C; Hoog-Labouret N; de Kievit F; Howarth K; Morris C; Green E; Friboulet L; Chabaud S; Guichou JF; Perol M; Besse B; Blay JY; Saintigny P; Planchard D
Clin Cancer Res; 2020 Dec; 26(23):6242-6253. PubMed ID: 32859654
[TBL] [Abstract] [Full Text] [Related]
20. SOX9 Is Essential for Triple-Negative Breast cancer Cell Survival and Metastasis.
Ma Y; Shepherd J; Zhao D; Bollu LR; Tahaney WM; Hill J; Zhang Y; Mazumdar A; Brown PH
Mol Cancer Res; 2020 Dec; 18(12):1825-1838. PubMed ID: 32661114
[TBL] [Abstract] [Full Text] [Related]
[Next]
